Vorinostat
A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4–4.4 months in earlier studies). Further brain tumor trials are planned in which vorinostat will be combined with other drugs.
Epstein Barr virus positive diffuse large B-cell lymphoma, not otherwise specified
Median survival 2 years, 25% 5-year survival.